Advertisement
Canada markets closed

  • S&P/TSX

    22,299.83
    +15.07 (+0.07%)
     

  • S&P 500

    5,297.10
    -11.05 (-0.21%)
     

  • DOW

    39,869.38
    -38.62 (-0.10%)
     

  • CAD/USD

    0.7340
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    79.42
    +0.19 (+0.24%)
     

  • Bitcoin CAD

    89,050.74
    -874.27 (-0.97%)
     

  • CMC Crypto 200

    1,376.13
    -17.91 (-1.28%)
     

  • GOLD FUTURES

    2,382.70
    -2.80 (-0.12%)
     

  • RUSSELL 2000

    2,096.25
    -13.21 (-0.63%)
     

  • 10-Yr Bond

    4.3770
    +0.0210 (+0.48%)
     

  • NASDAQ futures

    18,664.50
    +14.50 (+0.08%)
     

  • VOLATILITY

    12.42
    -0.03 (-0.24%)
     

  • FTSE

    8,438.65
    -7.15 (-0.08%)
     

  • NIKKEI 225

    38,758.59
    -161.67 (-0.42%)
     

  • CAD/EUR

    0.6756
    0.0000 (0.00%)
     

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation
·2 min read
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation

WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:

  • Barclays 26th Annual Global Healthcare Conference: Formal Presentation on March 12, 2024 at 2:05 pm ET

  • Jefferies Biotech on the Bay Summit: March 13, 2024

To access the live webcast of the presentation at the Barclays 26th Annual Global Healthcare Conference please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

ADVERTISEMENT

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com